跳至主要内容
临床试验/NCT04178148
NCT04178148已完成不适用

Personalized Dose Optimization of Amikacin Guided by Pharmacokinetic Modeling Software in Patients With Septic Shock

Centre Hospitalier Universitaire de Nīmes2 个研究点 分布在 1 个国家目标入组 180 人开始时间: 2019年11月25日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
180
试验地点
2
主要终点
Patients reaching target amikacin maximum concentration following second dose

研究概览

简要总结

Amikacin dose optimization is challenging in critically ill patients. The use of BestDose software algorithm-based drug optimization could help to achieve the recommended target concentrations (60-80 mg/L) after administration of the second dose of amikacin, associated with improved outcome. The study investigators hypothesize that 80% of patients undergoing drug dosing optimization using the BestDose software in the interventional group will reach the predefined PK/PD targets.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The patient or their legal representative must have given their free and informed consent and signed the consent form
  • The patient must be a member or beneficiary of a health insurance plan
  • The patient has septic shock according to the SEPSIS-3 definition in the 24 hours preceding inclusion, regardless of the source of infection
  • Patient having already received a first dose of amikacin in the 22 preceding hours
  • Patient with an expectation of receiving at least 2 doses of amikacin
  • Patient with available amikacin therapeutic drug monitoring

排除标准

  • The subject is participating in an interventional study that could influence the primary outcome, or is in a period of exclusion determined by a previous study
  • The patient is pregnant, parturient or breastfeeding
  • Patient has a contra-indication or an allergy to treatment by amikacin
  • Patient is not expected to survive beyond 48 hours

结局指标

主要结局

Patients reaching target amikacin maximum concentration following second dose

时间窗: 30 minutes after second dose of amikacin

Yes/no; Cmax 60-80mg/l

次要结局

  • Patients reaching target amikacin minimum concentration following third dose(24 hours after third dose of amikacin)
  • Patients reaching target amikacin minimum concentration following second dose(24 hours after second dose of amikacin)
  • Patients reaching target amikacin maximum concentration following third dose(30 minutes after third dose of amikacin)
  • Time taken to reach recommended Cmax during amikacin therapy(Maximum 7 days)
  • Clinical cure test(Day 7)
  • Number of days without renal replacement therapy(Day 28)
  • Number of days without vasopressors(Day 28)
  • Number of days without mechanical ventilation(Day 28)
  • Mortality(Day 28)

研究者

发起方
Centre Hospitalier Universitaire de Nīmes
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验